What is Certara, Inc.'s market cap?

Certara, Inc. (CERT) has a market capitalization of $1.2B and trades on NASDAQ.

What is Certara, Inc.'s revenue and profitability?

Certara, Inc. generated $419.7M in trailing twelve-month revenue with a net loss of $15.1M, representing a net margin of -3.6%. Gross margin stands at 61.6%, with free cash flow of $88.9M. These figures are based on the Q1 2026 filing.

Who are Certara, Inc.'s competitors?

Certara, Inc.'s key competitors include Simulations Plus, Schrodinger, IQVIA, and others. These companies compete in similar markets and product categories.

Who does Certara, Inc. partner with?

Certara, Inc.'s notable partners include Amazon Web Services, U.S. Food and Drug Administration, Pharmaceuticals and Medical Devices Agency, and others.

What subsidiaries does Certara, Inc. have?

Certara, Inc.'s subsidiaries include Simcyp.

Where is Certara, Inc. headquartered?

Certara, Inc. is headquartered in United States of America and employs approximately 1,391 people. It has been publicly traded since 2020.

Certara, Inc.

CERT

Certara is a global leader in biosimulation software and technology-enabled services, specializing in Model-Informed Drug Development (MIDD).

Market cap

$1.21B-27.4%

Revenue$419.7M+6.4%

Net income-$15.1M-8.8%

Free cash flow$88.9M-3.3%

EPS (diluted)-$0.10-11.1%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 11, 2026

Revenue$106.9MBeat by $785.0K EPS$0.09Miss by $0.02

Read the full report

Next report

Aug 4, 2026 (In 6 days)

Revenue estimate$98.1M

EPS estimate$0.10

Financials

Q1 2026

Income statement

See full

Revenue$106.9M+0.9%

Gross profit$65.3M+1.3%

Operating income-$4.3M-156%

Net income-$8.8M-285%

EPS (diluted)-$0.06-300%

Balance sheet

See full

Cash & equivalents$149.5M-16.5%

Total debt$304.0M-1.7%

Total equity$1.0B-6.2%

Total assets$1.5B-3.9%

Cash flow

See full

Operating cash flow$11.7M-32.6%

CapEx$631.0K+5.2%

Free cash flow$11.1M-34.0%

Valuation & ratios

Valuation

See full

Market cap$1.21B-27.4%

Enterprise value$1.36B-29.9%

P/S2.9×-1.6×

Profitability

See full

Gross margin61.6%+1.3pp

Operating margin2.2%—

Net margin-3.6%—

FCF margin21.2%-2.1pp

Returns & leverage

See full

Return on equity-1.4%—

Debt / equity0.3×0.0×

Current ratio1.9×-0.9×

Segments

By geography

See full

Americas$70.3M-2.4%

EMEA$28.1M+9.0%

Asia Pacific$8.5M+3.4%

By segment

See full

Reportable Segment$106.9M+0.9%

Competitors

By market cap

IQVIA$35.6B+5.9%

Veeva Systems$31.6B-33.9%

Certara, Inc.$1.2B-32.9%

Schrodinger$1.1B-30.5%

Simulations Plus$370.7M+35.0%

Quanterix Corporation$172.9M-42.9%

Champions Oncology$84.2M-3.0%

Harvard Bioscience$27.0M+15.5%

By revenue growth

Veeva Systems+16.3%

Schrodinger+10.6%

IQVIA+8.2%

Quanterix Corporation+6.9%

Certara, Inc.+6.4%

Simulations Plus+2.1%

By net margin

Veeva Systems28.37%+1.0pp

Simulations Plus9.88%+88.5pp

IQVIA8.1%+0.2pp

Certara, Inc.-3.6%-0.1pp

Schrodinger-68.49%+4.4pp

Quanterix Corporation-71.86%-36.6pp

Profile

Certara is a global leader in biosimulation software and technology-enabled services, specializing in Model-Informed Drug Development (MIDD). The company provides proprietary mathematical models and AI-driven platforms that simulate biological processes to predict how drugs behave in the human body. Its core value proposition is to increase the probability of clinical success, accelerate regulatory approval timelines, and reduce the overall cost of drug development for the biopharmaceutical industry.

Competitive position

A dominant market leader in biosimulation with software used by 20 global regulatory agencies and involved in 90% of recent FDA novel drug approvals.

GeographiesGlobal, North America, Japan, China

Customer segmentsPharmaceutical Manufacturers, Biotechnology Firms, Regulatory Agencies, Academic Research Institutions

Business modelSubscription SaaS, Professional Services, Technology-enabled Services

SuppliersCloud infrastructure providers, Scientific literature and data sources, Preclinical and clinical trial data

CustomersGlobal pharmaceutical companies, Emerging biotech startups, Government health regulators, Medical researchers

CountryUnited States of America

Listed2020

Employees1.4K

CEOJon Resnick

SectorHealthcare

IndustryMedical - Healthcare Information Services

Websitecertara.com

FilingsSEC EDGAR

Ask your AI about Certara, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Certara, Inc.'s market cap?: Certara, Inc. (CERT) has a market capitalization of $1.2B and trades on NASDAQ.
What is Certara, Inc.'s revenue and profitability?: Certara, Inc. generated $419.7M in trailing twelve-month revenue with a net loss of $15.1M, representing a net margin of -3.6%. Gross margin stands at 61.6%, with free cash flow of $88.9M. These figures are based on the Q1 2026 filing.
Who are Certara, Inc.'s competitors?: Certara, Inc.'s key competitors include Simulations Plus, Schrodinger, IQVIA, and others. These companies compete in similar markets and product categories.
Who does Certara, Inc. partner with?: Certara, Inc.'s notable partners include Amazon Web Services, U.S. Food and Drug Administration, Pharmaceuticals and Medical Devices Agency, and others.
What subsidiaries does Certara, Inc. have?: Certara, Inc.'s subsidiaries include Simcyp.
Where is Certara, Inc. headquartered?: Certara, Inc. is headquartered in United States of America and employs approximately 1,391 people. It has been publicly traded since 2020.